We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Alphabet Inc | NASDAQ:GOOG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.38 | 1.37% | 176.26 | 176.26 | 176.27 | 176.34 | 174.05 | 174.60 | 7,010,593 | 16:45:38 |
From May 2019 to May 2024
By Colin Kellaher
AbbVie Inc. (ABBV) and Calico, a life-science company backed by Google parent Alphabet Inc. (GOOG), on Tuesday said they will each invest an additional $500 million to extend their collaboration on new therapies for patients with age-related diseases, including neurodegeneration and cancer.
The companies said Calico, led by former Genentech Chairman and Chief Executive Arthur Levinson, will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027.
AbbVie, the North Chicago, Ill., biopharmaceutical company, will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities.
The companies said they will share costs and profits equally.
Google and AbbVie launched the initial $1.5 billion partnership in 2014.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 26, 2018 08:55 ET (12:55 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Alphabet Chart |
1 Month Alphabet Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
